Cognitive dysfunctions in elderly cancer patients: A new challenge for oncologists

Cancer Treatment Reviews

Volumn 40, Issue 6, 2014, Pages 810-817

  Lange, Marie ^a,b,c,d,e,f   Rigal, Olivier ^g   Clarisse, Bénédicte ^f   Giffard, Bénédicte ^a,b,c,d,h   Sevin, Emmanuel ^f   Barillet, Marie ^f   Eustache, Francis ^a,b,c,d,h   Joly, Florence ^d,e,f  

^a Centre Cyceron   (France)

^b NORMANDIE UNIVERSITÉ   (France)

^c PSL RESEARCH UNIVERSITY   (France)

^d CAEN UNIVERSITY HOSPITAL   (France)

^e Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers'   (France)

^f CENTRE FRANÇOIS BACLESSE   (France)

^g CENTRE HENRI BECQUEREL   (France)

^h CHU CÔTE DE NACRE   (France)

Author keywords

Cancer; Chemotherapy; Cognition; Elderly; Oncogeriatric assessment

Indexed keywords

AGED; BREAST CANCER; CANCER PATIENT; CANCER RISK; CANCER SCREENING; CANCER THERAPY; CLINICAL EVALUATION; CLINICAL PRACTICE; COGNITION; COGNITIVE DEFECT; COGNITIVE RESERVE; DAILY LIFE ACTIVITY; DEMENTIA; DEPRESSION; EXECUTIVE FUNCTION; GERIATRIC ASSESSMENT; HIGH RISK BEHAVIOR; HUMAN; INFORMATION PROCESSING; LIFE EXPECTANCY; MEDICAL ONCOLOGIST; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; PATIENT COMPLIANCE; PATIENT RISK; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SOCIAL STATUS; SYSTEMATIC REVIEW (TOPIC); TREATMENT INDICATION;

CANCER; CHEMOTHERAPY; COGNITION; ELDERLY; ONCOGERIATRIC ASSESSMENT;

AGED; AGED, 80 AND OVER; AGING; ANTINEOPLASTIC AGENTS; COGNITION; COGNITION DISORDERS; COMORBIDITY; EXECUTIVE FUNCTION; GERIATRIC ASSESSMENT; HUMANS; MEMORY; NEOPLASMS; THINKING;

EID: 84899908489     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.03.003     Document Type: Review

References (100)

1. Balducci L., Fossa S.D. Rehabilitation of older cancer patients. Acta Oncol 2013, 52:233-238.
2. Vincent H., Caillet P., Paillaud E. Management of elderly cancer patients. Specificities related to psychological, cognitive and social aspects. NPG 2011, 243-249.
3. Fitch M.I., Armstrong J., Tsang S. Patients' experiences with cognitive changes after chemotherapy. Can Oncol Nurs J 2008, 18:180-192.
4. Koppelmans V., Breteler M.M., Boogerd W., Seynaeve C., Gundy C., Schagen S.B. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol 2012, 30:1080-1086.
5. Agrawal K., Onami S., Mortimer J.E., Pal S.K. Cognitive changes associated with endocrine therapy for breast cancer. Maturitas 2010.
6. Nelson C.J., Lee J.S., Gamboa M.C., Roth A.J. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer 2008, 113:1097-1106.
7. Ahles T.A., Saykin A.J., Noll W.W., et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 2003, 12:612-619.
8. Ahles T.A., Saykin A.J. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 2007, 7:192-201.
9. Johnson T., Monk T., Rasmussen L.S., et al. Postoperative cognitive dysfunction in middle-aged patients. Anesthesiology 2002, 96:1351-1357.
10. Meyers C.A., Albitar M., Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2005, 104:788-793.
11. Reichenberg A., Yirmiya R., Schuld A., et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001, 58:445-452.
12. Hurria A., Rosen C., Hudis C., et al. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc 2006, 54:925-931.
13. Salthouse T.A. The processing-speed theory of adult age differences in cognition. Psychol Rev 1996, 103:403-428.
14. De B.R., Palladino P. Decline in working memory updating through ageing: intrusion error analyses. Memory 2004, 12:75-89.
15. Clarys D., Bugaiska A., Tapia G., Baudouin A. Ageing, remembering, and executive function. Memory 2009, 17:158-168.
16. West R.L. An application of prefrontal cortex function theory to cognitive aging. Psychol Bull 1996, 120:272-292.
17. Raz N., Gunning F.M., Head D., et al. Selective aging of the human cerebral cortex observed in vivo: differential vulnerability of the prefrontal gray matter. Cereb Cortex 1997, 7:268-282.
18. Kalpouzos G., Chetelat G., Landeau B., et al. Structural and metabolic correlates of episodic memory in relation to the depth of encoding in normal aging. J Cogn Neurosci 2009, 21:372-389.
19. Bunce D., Batterham P.J., Mackinnon A.J., Christensen H. Depression, anxiety and cognition in community-dwelling adults aged 70 years and over. J Psychiatr Res 2012, 46:1662-1666.
20. Saczynski J.S., Beiser A., Seshadri S., Auerbach S., Wolf P.A., Au R. Depressive symptoms and risk of dementia: the Framingham Heart Study. Neurology 2010, 75:35-41.
21. Reid L.M., Maclullich A.M. Subjective memory complaints and cognitive impairment in older people. Dement Geriatr Cogn Disord 2006, 22:471-485.
22. Staff R.T. Reserve, brain changes, and decline. Neuroimaging Clin N Am 2012, 99-iv.
23. Stern Y. Cognitive reserve. Neuropsychologia 2009, 47:2015-2028.
24. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997, 80:1273-1283.
25. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. 2000.
26. Heflin L.H., Meyerowitz B.E., Hall P., et al. Cancer as a risk factor for long-term cognitive deficits and dementia. J Natl Cancer Inst 2005, 97:854-856.
27. Driver J.A., Beiser A., Au R., et al. Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study. BMJ 2012, 344:e1442.
28. Heck J.E., Albert S.M., Franco R., Gorin S.S. Patterns of dementia diagnosis in surveillance, epidemiology, and end results breast cancer survivors who use chemotherapy. J Am Geriatr Soc 2008, 56:1687-1692.
29. Baxter N.N., Durham S.B., Phillips K.A., Habermann E.B., Virning B.A. Risk of dementia in older breast cancer survivors: a population-based cohort study of the association with adjuvant chemotherapy. J Am Geriatr Soc 2009, 57:403-411.
30. Alonso A., Mosley T.H., Gottesman R.F., Catellier D., Sharrett A.R., Coresh J. Risk of dementia hospitalisation associated with cardiovascular risk factors in midlife and older age: the Atherosclerosis Risk in Communities (ARIC) study. J Neurol Neurosurg Psychiatry 2009, 80:1194-1201.
31. Seliger S.L., Siscovick D.S., Stehman-Breen C.O., et al. Moderate renal impairment and risk of dementia among older adults: the Cardiovascular Health Cognition Study. J Am Soc Nephrol 2004, 15:1904-1911.
32. Ahles T.A., Saykin A.J., McDonald B.C., et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 2010, 28:4434-4440.
33. Skaali T., Fossa S.D., Andersson S., Langberg C.W., Lehne G., Dahl A.A. Is psychological distress in men recently diagnosed with testicular cancer associated with their neuropsychological test performance?. Psychooncology 2011, 20:369-377.
34. Wefel J.S., Saleeba A.K., Buzdar A.U., Meyers C.A. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 2010, 116:3348-3356.
35. Ferguson R.J., McDonald B.C., Saykin A.J., Ahles T.A. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol 2007, 25:3866-3870.
36. de Ruiter M.B., Reneman L., Boogerd W., et al. Cerebral hyporesponsiveness and cognitive impairment 10years after chemotherapy for breast cancer. Hum Brain Mapp 2011, 32:1206-1219.
37. Kesler S.R., Kent J.S., O'Hara R. Prefrontal cortex and executive function impairments in primary breast cancer. Arch Neurol 2011, 68:1447-1453.
38. Silverman D.H., Dy C.J., Castellon S.A., et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10years after chemotherapy. Breast Cancer Res Treat 2007, 103:303-311.
39. Ahles T.A., Saykin A.J., Furstenberg C.T., et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002, 20:485-493.
40. Buckwalter J.G., Crooks V.C., Petitti D.B. Cognitive performance of older women who have survived cancer. Int J Neurosci 2005, 115:1307-1314.
41. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198.
42. Brain E.G., Mertens C., Girre V., et al. Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trial. Crit Rev Oncol Hematol 2011, 80:160-170.
43. Chen H., Cantor A., Meyer J., et al. Can older cancer patients tolerate chemotherapy? A prospective pilot study. Cancer 2003, 97:1107-1114.
44. Extermann M., Meyer J., McGinnis M., et al. A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. Crit Rev Oncol Hematol 2004, 49:69-75.
45. Eberhardt B., Dilger S., Musial F., Wedding U., Weiss T., Miltner W.H. Short-term monitoring of cognitive functions before and during the first course of treatment. J Cancer Res Clin Oncol 2006, 132:234-240.
46. Minisini A.M., De Faccio S., Ermacora P., et al. Cognitive functions and elderly cancer patients receiving anticancer treatment: a prospective study. Crit Rev Oncol Hematol 2008, 67:71-79.
47. Kvale E.A., Clay O.J., Ross-Meadows L.A., et al. Cognitive speed of processing and functional declines in older cancer survivors: an analysis of data from the ACTIVE trial. Eur J Cancer Care (Engl) 2010, 19:110-117.
48. Yamada T.H., Denburg N.L., Beglinger L.J., Schultz S.K. Neuropsychological outcomes of older breast cancer survivors: cognitive features ten or more years after chemotherapy. J Neuropsychiatry Clin Neurosci 2010, 22:48-54.
49. Nguyen C.M., Yamada T.H., Beglinger L.J., Cavanaugh J.E., Denburg N.L., Schultz S.K. Cognitive features 10 or more years after successful breast cancer survival: comparisons across types of cancer interventions. Psychooncology 2013, 22:862-868.
50. Alibhai S.M., Breunis H., Timilshina N., et al. Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer. J Clin Oncol 2010, 28:5030-5037.
51. Jim H.S., Small B.J., Patterson S., Salup R., Jacobsen P.B. Cognitive impairment in men treated with luteinizing hormone-releasing hormone agonists for prostate cancer: a controlled comparison. Support Care Cancer 2010, 18:21-27.
52. Salminen E.K., Portin R.I., Koskinen A.I., Helenius H.Y., Nurmi M.J. Estradiol and cognition during androgen deprivation in men with prostate carcinoma. Cancer 2005, 103:1381-1387.
53. Mohile S.G., Lacy M., Rodin M., et al. Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer. Crit Rev Oncol Hematol 2010, 75:152-159.
54. Jenkins V., Shilling V., Fallowfield L., Howell A., Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology 2004, 13:61-66.
55. Schilder C.M., Eggens P.C., Seynaeve C., et al. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol 2009, 48:76-85.
56. Hermelink K., Henschel V., Untch M., Bauerfeind I., Lux M.P., Munzel K. Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study. Cancer 2008, 113:2431-2439.
57. Jim H.S., Donovan K.A., Small B.J., Andrykowski M.A., Munster P.N., Jacobsen P.B. Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer 2009, 115:1776-1783.
58. Ahles T.A., Root J.C., Ryan E.L. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol 2012, 30:3675-3686.
59. Conroy S.K., McDonald B.C., Smith D.J., et al. Alterations in brain structure and function in breast cancer survivors: effect of post-chemotherapy interval and relation to oxidative DNA damage. Breast Cancer Res Treat 2013, 137:493-502.
60. Alzheimer's Association. Adopt a brain-healthy diet. 2012.
61. Strittmatter W.J., Saunders A.M., Schmechel D., et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993, 90:1977-1981.
62. Vardy J., Wefel J.S., Ahles T., Tannock I.F., Schagen S.B. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 2008, 19:623-629.
63. Mitsiades N., Correa D., Gross C.P., Hurria A., Slovin S.F. Cognitive effects of hormonal therapy in older adults. Semin Oncol 2008, 35:569-581.
64. Seigers R., Fardell J.E. Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research. Neurosci Biobehav Rev 2011, 35:729-741.
65. Ganz P.A., Bower J.E., Kwan L., et al. Does tumor necrosis factor-alpha (TNF-alpha) play a role in post-chemotherapy cerebral dysfunction?. Brain Behav Immun 2013, 30(Suppl):S99-108.
66. Joly F., Rigal O., Noal S., Giffard B. Cognitive dysfunction and cancer: which consequences in terms of disease management?. Psychooncology 2011, 20:1251-1258.
67. Petersen R.C. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004, 256:183-194.
68. Von Ah D., Habermann B., Carpenter J.S., Schneider B.L. Impact of perceived cognitive impairment in breast cancer survivors. Eur J Oncol Nurs 2013, 17:236-241.
69. Reid-Arndt S.A., Yee A., Perry M.C., Hsieh C. Cognitive and psychological factors associated with early posttreatment functional outcomes in breast cancer survivors. J Psychosoc Oncol 2009, 27:415-434.
70. Hurria A., Goldfarb S., Rosen C., et al. Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. Breast Cancer Res Treat 2006, 98:343-348.
71. Pullens M.J., De Vries J., Roukema J.A. Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psychooncology 2010, 19:1127-1138.
72. Ownby R.L. Medication adherence and cognition. Medical, personal and economic factors influence level of adherence in older adults. Geriatrics 2006, 61:30-35.
73. Hayes T.L., Larimer N., Adami A., Kaye J.A. Medication adherence in healthy elders: small cognitive changes make a big difference. J Aging Health 2009, 21:567-580.
74. Ettenhofer M.L., Hinkin C.H., Castellon S.A., et al. Aging, neurocognition, and medication adherence in HIV infection. Am J Geriatr Psychiatry 2009, 17:281-290.
75. Robertson D.A., Savva G.M., Kenny R.A. Frailty and cognitive impairment-A review of the evidence and causal mechanisms. Ageing Res Rev 2013, 12:840-851.
76. Pal S.K., Katheria V., Hurria A. Evaluating the older patient with cancer: understanding frailty and the geriatric assessment. CA Cancer J Clin 2010, 60:120-132.
77. Katzman R., Brown T., Fuld P., Peck A., Schechter R., Schimmel H. Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. Am J Psychiatry 1983, 140:734-739.
78. Pfeiffer E. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc 1975, 23:433-441.
79. Borson S., Scanlan J.M., Chen P., Ganguli M. The Mini-Cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc 2003, 51:1451-1454.
80. Folstein MF, Fossa SD. Mini-Mental® State Examination, 2nd Edition™ (MMSE®-2™). PAR Edition; 2012.
81. Nasreddine Z.S., Phillips N.A., Bedirian V., et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005, 53:695-699.
82. Insel K., Morrow D., Brewer B., Figueredo A. Executive function, working memory, and medication adherence among older adults. J Gerontol B Psychol Sci Soc Sci 2006, 61:102-107.
83. Brickenkamp R. Test D'attention Concentrée: D2 1998, Editions du Centre de Psychologie Appliquée, Paris.
84. Wechsler D. Wechsler Adult Intelligence Scale-III 1997, The Psychological Corporation, San Antonio.
85. Van der Linden M., Adam S., Agniel A., et al. Assessment of Memory Impairment 2004, Solal, Marseille.
86. Andreis F., Ferri M., Mazzocchi M., et al. Lack of a chemobrain effect for adjuvant FOLFOX chemotherapy in colon cancer patients. A pilot study. Support Care Cancer 2013, 21:583-590.
87. Benton A.L., Hamsher K.D.S. Multilingual Aphasia Examination 1989, AJA Associates, Iowa City.
88. Shapiro A.M., Benedict R.H., Schretlen D., Brandt J. Construct and concurrent validity of the Hopkins Verbal Learning Test-revised. Clin Neuropsychol 1999, 13:348-358.
89. Delis D.C., Kramer J.H., Kaplan E., Ober B.A. The California Verbal Learning Test: Research edition 1987, The Psychological Corporation ed.
90. Heaton R.K., Chelune G.J., Talley J.L., Kay G.G., Curtis G. Wisconsin Card Sorting Test (WCST) Manual 1993, revised and expanded, Psychosocial Assessment Ressources ed., Odessa, FL.
91. Reitan R. Validity of trail making tests as an indicator of organic brain damage. Percept Mot Skills 1958, 8:271-276.
92. Stroop J.R. Studies of interference in serial verbal reactions. J Exp Psychol 1935.
93. Wilkinson G.S. WRAT3 Administration Manual 1993, Wilmington DE, Wide Range.
94. Lundorff L.E., Jonsson B.H., Sjogren P. Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial. Palliat Med 2009, 23:731-738.
95. Kohli S., Fisher S.G., Tra Y., et al. The effect of modafinil on cognitive function in breast cancer survivors. Cancer 2009, 115:2605-2616.
96. Von Ah D., Storey S., Jansen C.E., Allen D.H. Coping strategies and interventions for cognitive changes in patients with cancer. Semin Oncol Nurs 2013, 29:288-299.
97. Schuurs A., Green H.J. A feasibility study of group cognitive rehabilitation for cancer survivors: enhancing cognitive function and quality of life. Psychooncology 2013, 22:1043-1049.
98. Von A.D., Carpenter J.S., Saykin A., et al. Advanced cognitive training for breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat 2012, 135:799-809.
99. McDougall G.J., Becker H., Acee T.W., Vaughan P.W., Delville C.L. Symptom management of affective and cognitive disturbance with a group of cancer survivors. Arch Psychiatr Nurs 2011, 25:24-35.
100. Hurria A., Togawa K., Mohile S.G., et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011, 29:3457-3465.